サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1774810

脳炎治療の世界市場

Encephalitis Treatment

出版日
ページ情報
英文 478 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.79円
脳炎治療の世界市場
出版日: 2025年07月23日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 478 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

脳炎治療の世界市場は2030年までに275億米ドルに到達

2024年に216億米ドルと推定される脳炎治療の世界市場は、2024～2030年の分析期間においてCAGR 4.1%で成長し、2030年には275億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである一次脳炎は、CAGR 4.8%を記録し、分析期間終了時には182億米ドルに達すると予測されます。二次性脳炎分野の成長率は、分析期間中CAGR 2.7%と推定されます。

米国市場は59億米ドルと推定、中国はCAGR 7.7%で成長予測

米国の脳炎治療市場は2024年に59億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに57億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と3.2%と予測されています。欧州では、ドイツがCAGR 2.4%で成長すると予測されています。

世界の脳炎治療市場- 主要動向と促進要因まとめ

脳炎とは何か、なぜ効果的な治療が重要なのか？

脳炎は、脳の炎症を特徴とする重篤な神経疾患であり、多くの場合、ウイルス感染、自己免疫疾患、または細菌性病原体によって引き起こされます。脳炎を治療せずに放置しておくと、長期にわたる神経合併症、痙攣、認知機能障害を引き起こし、重症の場合は死に至ることもあります。日本脳炎、西ナイル・ウイルス、ジカ・ウイルスなど、蚊が媒介する脳炎ウイルスの増加により、この疾患の世界の負担が増加しています。さらに、単純ヘルペスウイルス（HSV）誘発脳炎や自己免疫性脳炎の有病率の上昇により、効果的な抗ウイルス療法や免疫調節療法の需要が高まっています。

ポリメラーゼ連鎖反応（PCR）検査、脳脊髄液分析、MRI画像診断などの早期診断法が利用可能になったことで、治療成績が向上し、タイムリーな医療介入が可能になりました。病院や研究機関は、特にアジア、アフリカ、ラテンアメリカの高リスク地域において、ウイルス性脳炎に対抗するための標的療法やワクチン開発に積極的に投資しています。また、蚊が媒介する脳炎の発生を抑制するための予防接種プログラムや公衆衛生への取り組みに注目が集まっていることも、市場の成長を後押ししています。

脳炎治療の最新動向は？

脳炎治療における最近の進歩には、新規抗ウイルス剤、モノクローナル抗体、免疫調整療法などがあります。ウイルス性脳炎では、単純ヘルペスウイルス（HSV）脳炎の主要な治療薬はアシクロビルであるが、新しい広域抗ウイルス薬が新興ウイルス株の治療薬として検討されています。免疫療法、特に免疫グロブリン静注（IVIG）と副腎皮質ステロイドは、自己免疫性脳炎の治療に有望な結果を示しています。

さらに研究者は、特に流行地域において、脳炎を引き起こすウイルスを予防するためのmRNAベースのワクチンや次世代免疫戦略を開発しています。AIを活用した診断プラットフォームも早期発見と治療計画を改善し、合併症のリスクを減らしています。精密医療アプローチの統合が重視されるようになったことで、脳炎管理におけるイノベーションが促進され、生存率と長期的な回復転帰が改善されると期待されています。

脳炎治療市場の成長の原動力は？

脳炎治療市場の成長は、ウイルス発生の増加、希少神経疾患研究への資金提供の増加、抗ウイルスおよび免疫療法治療の進歩によってもたらされます。特にリスクの高い地域でのワクチンプログラムの拡大は、疾病予防の意識向上とヘルスケア投資につながっています。さらに、神経学研究におけるAIの利用の増加、診断能力の向上、医薬品開発における製薬企業との提携が市場開拓を後押ししています。

政府の公衆衛生への取り組み、パンデミック対策プログラム、蚊の駆除対策の急増も市場拡大に寄与しています。神経学的合併症を起こしやすい老年人口の増加も、脳炎治療への需要を高める大きな要因です。研究が進化を続ける中、遺伝子治療、生物製剤、個別化医療アプローチにおけるブレークスルーが、脳炎患者の治療選択肢をさらに拡大すると期待されています。

セグメント

疾患タイプ（一次性脳炎、二次性脳炎）;治療法（抗ウイルス剤、ステロイド注射、抗生物質、免疫グロブリン療法、プラズマフェレーシス、その他の治療法）;投与経路（経口、非経口、その他）;エンドユーザー（病院、専門クリニック、その他のエンドユーザー）

調査対象企業の例

  • Amgen, Inc.
  • Arialys Therapeutics
  • Basilea Pharmaceutica Ltd.
  • Bavarian Nordic A/S
  • Bayer AG
  • Bharat Biotech International Ltd.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Sanofi SA

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP30774

Global Encephalitis Treatment Market to Reach US$27.5 Billion by 2030

The global market for Encephalitis Treatment estimated at US$21.6 Billion in the year 2024, is expected to reach US$27.5 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Primary encephalitis, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$18.2 Billion by the end of the analysis period. Growth in the Secondary encephalitis segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.9 Billion While China is Forecast to Grow at 7.7% CAGR

The Encephalitis Treatment market in the U.S. is estimated at US$5.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.7 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Encephalitis Treatment Market - Key Trends & Drivers Summarized

What Is Encephalitis, and Why Is Effective Treatment Critical?

Encephalitis is a severe neurological condition characterized by inflammation of the brain, often caused by viral infections, autoimmune disorders, or bacterial pathogens. If left untreated, encephalitis can lead to long-term neurological complications, seizures, cognitive impairments, and, in severe cases, fatality. The growing incidence of mosquito-borne encephalitis viruses such as Japanese encephalitis, West Nile virus, and Zika virus has contributed to the increasing global burden of this disease. Additionally, the rising prevalence of herpes simplex virus (HSV)-induced encephalitis and autoimmune encephalitis has led to higher demand for effective antiviral and immunomodulatory therapies.

The availability of early diagnosis methods, such as polymerase chain reaction (PCR) testing, cerebrospinal fluid analysis, and MRI imaging, has improved treatment outcomes, enabling timely medical intervention. Hospitals and research institutions are actively investing in targeted therapies and vaccine development to combat viral-induced encephalitis, particularly in high-risk regions of Asia, Africa, and Latin America. The increasing focus on preventive vaccination programs and public health initiatives to curb mosquito-borne encephalitis outbreaks has also fueled market growth.

What Are the Latest Advancements in Encephalitis Treatment?

Recent advancements in encephalitis treatment include novel antiviral agents, monoclonal antibodies, and immune-modulating therapies. For viral encephalitis, acyclovir remains the primary treatment for herpes simplex virus (HSV) encephalitis, while newer broad-spectrum antiviral drugs are being explored for treating emerging viral strains. Immunotherapy, particularly intravenous immunoglobulin (IVIG) and corticosteroids, has shown promising results in managing autoimmune encephalitis cases.

Additionally, researchers are developing mRNA-based vaccines and next-generation immunization strategies to prevent encephalitis-causing viruses, particularly in endemic regions. AI-powered diagnostic platforms are also improving early detection and treatment planning, reducing the risk of complications. The growing emphasis on integrating precision medicine approaches is expected to drive innovation in encephalitis management, improving survival rates and long-term recovery outcomes.

What Is Driving the Growth of the Encephalitis Treatment Market?

The growth in the encephalitis treatment market is driven by rising viral outbreaks, increased funding for rare neurological disease research, and advancements in antiviral and immunotherapy treatments. The expansion of vaccine programs, particularly in high-risk regions, has led to greater disease prevention awareness and healthcare investments. Additionally, the increasing use of AI in neurology research, improved diagnostic capabilities, and pharmaceutical collaborations in drug development has propelled market expansion.

The surge in government public health initiatives, pandemic preparedness programs, and mosquito control measures has also contributed to market growth. The rising geriatric population, who are more susceptible to neurological complications, is another significant factor increasing demand for encephalitis treatments. As research continues to evolve, breakthroughs in gene therapy, biologics, and personalized medicine approaches are expected to further expand treatment options for encephalitis patients.

SCOPE OF STUDY:

The report analyzes the Encephalitis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Primary encephalitis, Secondary encephalitis); Treatment (Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis, Other treatments); Administration Route (Oral, Parenteral, Others); End-Use (Hospitals, Specialty clinics, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Amgen, Inc.
  • Arialys Therapeutics
  • Basilea Pharmaceutica Ltd.
  • Bavarian Nordic A/S
  • Bayer AG
  • Bharat Biotech International Ltd.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Sanofi SA

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Encephalitis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Viral Encephalitis Boosts Demand for Rapid Diagnostic and Treatment Solutions
    • Increased Vector-Borne Disease Transmission Drives Market for Antiviral and Anti-Inflammatory Therapies
    • Hospital ICU Expansion and Neurology Department Growth Strengthen Access to Encephalitis Management
    • Advancements in Imaging and Biomarkers Support Early Diagnosis and Targeted Drug Intervention
    • Immunocompromised Populations Spur Use of Prophylactic and Broad-Spectrum Encephalitis Treatments
    • Cross-Border Travel and Migration Patterns Raise Risk of Arboviral and Parainfectious Encephalitis
    • Neurocritical Care Protocol Development Enhances Standardization of Encephalitis Treatment Regimens
    • Development of Vaccine-Based Prophylaxis for Tick-Borne and Japanese Encephalitis Drives Prevention-Oriented Markets
    • Increased Awareness and Government Surveillance Initiatives Improve Early Case Detection and Access to Care
    • Rising Use of Immunoglobulin Therapy and Corticosteroids Supports Clinical Response in Autoimmune Cases
    • Biopharma R&D Pipelines Expand With Monoclonal Antibody-Based Treatments for Encephalitis
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Encephalitis Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Encephalitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Encephalitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Encephalitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Primary encephalitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Primary encephalitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Primary encephalitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Secondary encephalitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Secondary encephalitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Secondary encephalitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Specialty clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Specialty clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Specialty clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Antiviral agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Antiviral agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Antiviral agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Steroid injections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Steroid injections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Steroid injections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Immunoglobulin therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Immunoglobulin therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Immunoglobulin therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Plasmapheresis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Plasmapheresis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Plasmapheresis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Other treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Other treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Other treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • JAPAN
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • CHINA
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • EUROPE
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Encephalitis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Encephalitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • FRANCE
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 110: France Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • GERMANY
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 146: UK Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: UK 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Spain 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Spain 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Spain 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Russia 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Russia 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Russia 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Europe 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Encephalitis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Encephalitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Australia 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Australia 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Australia 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • INDIA
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 221: India Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: India 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: India 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 230: India Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: India Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: India 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: South Korea 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: South Korea 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: South Korea 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Encephalitis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Encephalitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Latin America 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Latin America 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Latin America 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Argentina 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Argentina 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Argentina 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Brazil 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Brazil 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Brazil Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Brazil 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Mexico 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Mexico 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Mexico Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Mexico 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Rest of Latin America 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Encephalitis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Encephalitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Middle East 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Middle East 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Middle East 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Iran 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Iran 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 344: Iran Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Iran Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Iran 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Israel 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Israel 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 356: Israel Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Israel Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Israel 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Saudi Arabia 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: UAE 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: UAE 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 380: UAE Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: UAE Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: UAE 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Rest of Middle East 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • AFRICA
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Africa 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Africa 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 404: Africa Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Africa Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 406: Africa 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030

IV. COMPETITION